WXXWY:OTCMKTS
Wuxi Biologics Cayman ADR
$12.60
arrow_upward
+0.32%(+0.040) 1D
Okt 19, 11:49:57 AM GMT-4 · USD
search
Lahat ng simbolo
| Simbolo | Presyo | Palitan | % ng Pagbabago |
|---|
insights_autoBumubuo ng mga nangungunang insight para sa WXXWY...
Buksan
$12.19
Mataas
$12.65
Mababa
$12.19
Mkt. cap
198.43B
Avg. na dami
64.29K
Dami
6.81K
Mataas nang 52-wk
$14.80
Mababa nang 52-wk
$7.30
Beta
0.01
Mga natitirang share
2.06B
Bilang ng mga empleyado
15K
Buksan
$12.19
Mataas
$12.65
Mababa
$12.19
Mkt. cap
198.43B
Avg. na dami
64.29K
Dami
6.81K
Mataas nang 52-wk
$14.80
Mababa nang 52-wk
$7.30
Beta
0.01
Mga natitirang share
2.06B
Bilang ng mga empleyado
15K
Mga balita at kwento
Mula sa mga source sa web at partner sa balita
Investing.com
·
4 oras ang nakalipas
Dow Jones, Nasdaq, S&P 500 preview: All eyes on Meta, Tesla, SpaceX earnings
The Motley Fool
·
5 araw ang nakalipas
The S&P 500 Is Dangerously Concentrated in 5 Tech Giants. Are They Still Buys?
24/7 Wall St.
·
5 araw ang nakalipas
These 3 International Dividend ETFs Outyield SCHD and Are Beating the S&P 500 Over the Past Year
FXStreet
·
4 araw ang nakalipas
Dow Jones futures gains ahead of US PPI, Retail Sales data
Profile
WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development.
WuXi Biologics' roots date back to 2010, when it was founded as a division of WuXi AppTec and began building out capabilities and facilities required for biologics discovery, development and good manufacturing practices. After being spun off from its parent, WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017.
As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore.
In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong.
In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia
Tungkol sa Wuxi Biologics Cayman ADR